stockrow
Friday 6 November 2026
Export LEGN’s income statement to Excel — free account
Legend Biotech Corporation Sponsored ADR
LEGN Healthcare Biotechnology
Legend Biotech Corporation Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 64.0% from fiscal 2024.
- Revenue
- +51.9%
- EPS
- +126.1%
- Free cash flow
- −26.8%
- Total debt
- −49.6%
Quarter to June 2026, against a year earlier
23.45
0.91
+4.04%
Follow LEGN
Alert me
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 3 | 3 | 3 | 6 | 5 | 3 |
P/E ratio |
1.43 | 3.40 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | 4.88 | 11.75 | 8.58 | 11.84 | 7.25 | 4.54 |
P/S ratio |
0.00 | 0.00 | 56.44 | 40.68 | 95.39 | 81.88 | 46.04 | 11.08 | 3.89 |
Altman Z″-Score (non-manufacturers) |
— | 2.63 | (2.94) | 3.78 | 6.33 | 4.80 | 7.45 | 6.92 | 4.47 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | — | (4.79) | (2.03) | (3.32) | (2.81) | 417.49 | (2.43) | (2.08) |
P/Operating CF |
0.00 | 0.00 | (80.79) | (59.47) | (94.40) | (52.00) | (36.05) | (72.52) | (328.32) |
P/B ratio |
0.00 | 0.00 | 0.00 | 11.87 | 8.57 | 10.59 | 8.57 | 5.72 | 4.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 11.99 | 8.62 | 10.64 | 8.60 | 5.73 | 4.01 |
EV/Sales |
0.00 | 0.00 | 55.04 | 34.53 | 84.31 | 73.94 | 41.64 | 9.56 | 3.45 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
0.00 | 0.00 | (28.96) | (12.66) | (29.24) | (20.67) | (14.15) | (35.64) | (35.42) |
EV/FCF |
0.00 | 0.00 | (16.48) | (8.25) | (17.76) | (15.17) | (13.39) | (32.34) | (27.43) |
Quick Ratio |
4.44 | 1.52 | 1.48 | 3.61 | 4.08 | 3.45 | 6.51 | 4.07 | 1.51 |
Current Ratio |
4.44 | 2.05 | 1.62 | 3.68 | 4.14 | 3.69 | 6.92 | 4.62 | 1.96 |
Net Debt/EBITDA |
(0.14) | (1,419.03) | 1.23 | 2.35 | 1.97 | 1.74 | 2.62 | 4.66 | 2.31 |
Debt/Assets |
0.00% | 1.17% | 2.09% | 0.55% | 10.85% | 19.91% | 15.22% | 18.03% | 18.41% |
Debt/Equity |
0.00 | 0.58 | (0.05) | 0.01 | 0.16 | 0.36 | 0.22 | 0.29 | 0.32 |
Asset Turnover |
0.07 | 0.29 | 0.18 | 0.16 | 0.07 | 0.10 | 0.18 | 0.36 | 0.60 |
Operating CF/Net income |
(0.25) | (110.52) | 0.62 | 0.73 | 0.49 | 0.45 | 0.76 | 0.81 | 0.34 |
Capex/Depreciation |
0.00 | (12.48) | (7.43) | (5.01) | (3.26) | (1.21) | (1.11) | (0.66) | (0.99) |
Interest Coverage |
9,187.33 | — | — | — | — | — | — | — | — |
| 89.19% | (26.96%) | 232.83% | (385.65%) | (77.15%) | (59.11%) | (51.94%) | (15.45%) | (29.06%) | |
| 2.80% | (1.30%) | (37.10%) | (60.17%) | (43.86%) | (36.43%) | (32.60%) | (10.06%) | (17.44%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (7,010.37%) | 0.00% | (115.31%) | (56.37%) | (50.54%) |
Return on Tangible Assets |
5.15% | (1.42%) | (88.99%) | (55.71%) | (49.03%) | (49.24%) | (37.28%) | (16.01%) | (40.83%) |
Average Days of Receivables |
3,542.64 | 151.83 | 170.01 | 334.58 | 267.34 | 0.28 | 128.06 | 3.72 | 4.65 |
Research and Development Expense of Revenue |
34.73% | 96.20% | 251.51% | 283.83% | 455.27% | 286.87% | 134.04% | 65.92% | 40.31% |
Selling, General and Administrative Expense of Revenue |
5.94% | 6.23% | 50.28% | 88.90% | 217.22% | 148.75% | 70.47% | 45.32% | 33.20% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.00 | 0.00 | (0.07) | 0.05 | 0.09 | 0.07 | 0.08 | 0.11 | 0.13 |
Graham Number |
0.00 | 0.00 | 6.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
70.00% | 29.41% | (4.46%) | (9.12%) | (6.15%) | (4.41%) | (4.54%) | (3.72%) | (7.41%) |
Free Cash Flow Yield |
0.00% | 0.00% | (5.92%) | (10.28%) | (4.98%) | (5.95%) | (6.76%) | (2.67%) | (3.23%) |
Revenue per Share |
0.15 | 0.63 | 0.64 | 0.69 | 0.49 | 0.74 | 1.62 | 3.43 | 5.58 |
Operating CF per Share |
(0.02) | 3.08 | (0.83) | (1.89) | (1.41) | (1.27) | (2.23) | (0.79) | (0.54) |
Capex per Share |
0.00 | (0.21) | (0.39) | (0.42) | (0.32) | (0.14) | (0.13) | (0.08) | (0.16) |
Free Cash Flow per Share |
(0.02) | 2.87 | (1.22) | (2.31) | (1.73) | (1.41) | (2.36) | (0.86) | (0.70) |
Cash per Share |
0.01 | 2.16 | 1.59 | 4.28 | 6.27 | 6.46 | 7.43 | 6.14 | 5.15 |
Shareholders Equity per Share |
0.08 | 0.09 | (1.23) | 2.37 | 5.44 | 4.68 | 7.11 | 5.69 | 5.44 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.08 | 0.09 | (1.23) | 2.37 | 5.44 | 4.68 | 7.11 | 5.69 | 5.44 |
Free Cash Flow |
(2.38) | 286.68 | (122.16) | (272.78) | (243.86) | (223.56) | (416.00) | (158.10) | (128.80) |
Working Capital |
179.00 | 167.77 | 79.34 | 431.69 | 720.65 | 801.33 | 1,281.38 | 1,006.20 | 610.70 |
Capital Expenditures |
(0.89) | (21.00) | (39.10) | (49.77) | (45.40) | (22.27) | (22.72) | (14.10) | (28.60) |
Net Current Asset Value |
4.00 | (93.44) | (203.48) | 152.11 | 596.33 | 512.47 | 900.56 | 654.30 | 515.50 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.33 | 0.61 | 0.61 | 0.66 | 0.19 | 0.08 | 0.02 | 0.03 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.07 | 0.06 | 0.08 | 0.09 | 0.14 | 0.17 | 0.19 | 0.22 | 0.25 |
Cash ROIC |
(16.97%) | 124.60% | (288.73%) | (34.51%) | (13.77%) | (10.98%) | (14.64%) | (6.42%) | (5.67%) |
Accounts Receivable Turnover |
0.14 | 0.49 | 2.29 | 1.56 | 1.10 | 4.63 | 5.70 | 11.79 | 105.53 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.27 | 4.54 | 6.78 | 6.71 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.80 | 9.68 | 10.83 | 14.60 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 183.68 | 77.59 | 60.06 | 74.23 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 57.82 | 49.18 | 37.18 | 28.62 |
Average Receivables |
169.00 | 127.61 | 28.11 | 52.48 | 62.69 | 25.25 | 50.07 | 53.22 | 9.75 |
Average Payables |
5.50 | 5.79 | 8.58 | 7.41 | 6.14 | 19.97 | 31.77 | 34.63 | 60.80 |
Average Inventory |
0.50 | 0.57 | 1.15 | 1.48 | 1.77 | 6.05 | 14.89 | 21.67 | 27.95 |
Average Assets |
334.00 | 214.52 | 358.38 | 504.36 | 920.24 | 1,225.21 | 1,589.79 | 1,759.40 | 1,701.95 |
Average Common Equity |
10.50 | 10.32 | (57.11) | 78.69 | 523.10 | 755.13 | 997.84 | 1,145.99 | 1,021.35 |
Columns are period end dates · fundamentals updated 26 Oct 2026